RAC1 and breast carcinoma: Since RAC1 inhibitor NSC23766 is capable of combating breast cancer and lung cancer (Zuo et al., 2006; Hernandez et al., 2010; Yoshida et al., 2010; Chen et al., 2011), the antitumoral effects of β-elemene may also involve the same pathway.